Innovative Technology Harbour BioMed's proprietary antibody platforms, including Harbour Mice® and Hu-mAtrIx(TM), enable the development of next-generation fully human monoclonal antibodies and AI-driven HCAb models, offering opportunities to supply advanced therapeutics and discovery services to pharmaceutical companies seeking cutting-edge biologics.

Strategic Collaborations Recent partnerships with companies like Dc Lnc and Otsuka Pharmaceuticals demonstrate Harbour BioMed's active engagement with industry leaders, creating potential pathways for joint development projects, licensing deals, and co-commercialization opportunities across oncology and immunology markets.

Expanding Pipeline With a focus on immunology and oncology and ongoing clinical data presentations, Harbour BioMed's robust and diverse pipeline positions it as a potential supplier of promising antibody therapeutics and research tools to global biopharma firms expanding their portfolios.

Financial Robustness Generating revenues between 250 to 500 million USD and securing substantial funding of over 100 million USD, Harbour BioMed has the financial capacity to invest in collaborative R&D projects and large-scale licensing agreements, which can be leveraged for new client acquisition.

Market Leadership As a publicly listed company on HKEX with a focus on innovative antibody discovery, Harbour BioMed is well-positioned as a reliable partner for pharmaceutical companies seeking high-quality biological research and development services, particularly in antibody engineering and AI-powered therapeutics.